Investigating the efficacy of acupuncture in treating patients with metabolic-associated fatty liver disease: a protocol for a randomised controlled clinical trial.
Study Goal
The researchers aimed to determine the efficacy of acupuncture versus sham acupuncture for treating metabolic-associated fatty liver disease (MAFLD).
Results Summary
The study protocol outlines a rigorous trial design to assess acupuncture's impact on liver fat reduction, metabolic markers, and gut microbiota, but results are not yet available as this is a protocol description.
Population
98 participants with MAFLD.
Effective Dosage
Not specified (frequency/duration: 12 weeks).
Duration
12 weeks of intervention, with follow-up at 24 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
acupuncture | neutral | metabolic-associated fatty liver disease (MAFLD) treatment | participants with MAFLD | - | determine the efficacy | #1 |
acupuncture versus sham acupuncture (SHA) | neutral | MAFLD treatment | participants with MAFLD | - | determine the efficacy | #2 |
acupuncture or SHA | decrease | liver fat after 12 weeks of treatment in MRI-proton density fat fraction (MRI-PDFF) | participants with MAFLD | 30% relative decline | primary outcome is the rate of patients with a 30% relative decline | #3 |
acupuncture or SHA | neutral | relative liver fat content measured by MRI-PDFF | participants with MAFLD | - | secondary outcomes include the changes | #4 |
acupuncture or SHA | neutral | magnetic resonance elastography | participants with MAFLD | - | secondary outcomes include the changes | #5 |
acupuncture or SHA | neutral | liver function | participants with MAFLD | - | secondary outcomes include the changes | #6 |
acupuncture or SHA | neutral | lipid metabolism | participants with MAFLD | - | secondary outcomes include the changes | #7 |
acupuncture or SHA | neutral | homeostatic model assessment for insulin resistance (HOMA-IR) | participants with MAFLD | - | secondary outcomes include the changes | #8 |
acupuncture or SHA | neutral | serum high sensitivity C reactive protein | participants with MAFLD | - | secondary outcomes include the changes | #9 |
acupuncture or SHA | neutral | body mass index | participants with MAFLD | - | body measurement indicators | #10 |
acupuncture or SHA | neutral | waist circumference | participants with MAFLD | - | body measurement indicators | #11 |
acupuncture or SHA | neutral | hip circumference | participants with MAFLD | - | body measurement indicators | #12 |
acupuncture or SHA | neutral | waist-to-hip ratio | participants with MAFLD | - | body measurement indicators | #13 |
acupuncture or SHA | neutral | gut microbiota composition | participants with MAFLD | - | alteration | #14 |
acupuncture or SHA | neutral | gut microbiota metabolism | participants with MAFLD | - | alteration | #15 |
INTRODUCTION: Acupuncture is widely used for metabolic-associated fatty liver disease (MAFLD) treatment; however, the clinical efficacy has not been confirmed due to the lack of high-level evidence-based clinical practice. The purpose of this study is to design a research protocol that will be used to determine the efficacy of acupuncture versus sham acupuncture (SHA) for MAFLD treatment. METHODS AND ANALYSIS: This will be a multicentre, randomised and sham-controlled trial. Ninety-eight participants with MAFLD will be enrolled in this trial. Participants will be randomly assigned in a 1:1 ratio to receive acupuncture or SHA for 12 weeks. The primary outcome is the rate of patients with a 30% relative decline in liver fat after 12 weeks of treatment in MRI-proton density fat fraction (MRI-PDFF), which will be obtained by quantitative chemical shift imaging such as the multipoint Dixon method at 0, 12 and 24 weeks. Secondary outcomes include the changes in the relative liver fat content measured by MRI-PDFF, magnetic resonance elastography, liver function, lipid metabolism, homeostatic model assessment for insulin resistance (HOMA-IR) and serum high sensitivity C reactive protein, which will be obtained at 0, 6, 12 and 24 weeks. Body measurement indicators (body mass index, waist circumference, hip circumference and waist-to-hip ratio) will be obtained at 0, 3, 6, 9, 12 and 24 weeks. The alteration in the gut microbiota composition and its metabolism will be assessed by 16S ribosomal RNA sequencing and liquid chromatography-mass spectrometry at 0 and 12 weeks. ETHICS AND DISSEMINATION: This study protocol has been approved by the ethics committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (2023-1347-114-01). The results of this study will be published in a peer-reviewed journal and presented at academic conferences. TRIAL REGISTRATION NUMBER: ChiCTR2300075701.